G1 Therapeutics Reaffirms FY24 COSELA Revenue Of $60M-$70M
Portfolio Pulse from Benzinga Newsdesk
G1 Therapeutics has reaffirmed its full year 2024 revenue guidance for COSELA, expecting to generate between $60 million and $70 million. The company also anticipates a 25% to 30% reduction in operational expenses compared to the prior year, aiming for profitability in the second half of 2025.
August 08, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
G1 Therapeutics reaffirms its FY24 COSELA revenue guidance of $60M-$70M and expects a significant reduction in operational expenses, aiming for profitability in H2 2025.
The reaffirmation of revenue guidance and expected reduction in operational expenses are positive indicators for G1 Therapeutics. The company's aim for profitability in the second half of 2025 further boosts investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100